Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Drug shortages, public health threat continues, despite efforts to help ensure product availability : report to congressional addressees
| Drug shortages, public health threat continues, despite efforts to help ensure product availability : report to congressional addressees |
| Pubbl/distr/stampa | [Washington, D.C.] : , : United States Government Accountability Office, , 2014 |
| Descrizione fisica | 1 online resource (iii, 88 pages) : illustrations |
| Soggetto topico |
Drugs - Supply and demand
Drug accessibility - United States Drugs - Prices - United States Pharmaceutical industry - United States |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Drug shortages, public health threat continues, despite efforts to help ensure product availability |
| Record Nr. | UNINA-9910702660803321 |
| [Washington, D.C.] : , : United States Government Accountability Office, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug shortages, threat to public health persists, despite actions to help maintain product availability : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives / / statement of Marcia Crosse
| Drug shortages, threat to public health persists, despite actions to help maintain product availability : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives / / statement of Marcia Crosse |
| Autore | Crosse Marcia |
| Pubbl/distr/stampa | [Washington, D.C.] : , : United States Government Accountability Office, , 2014 |
| Descrizione fisica | 1 online resource (9 pages) : color illustrations |
| Collana | Testimony |
| Soggetto topico |
Drugs - Supply and demand - United States
Drug accessibility - United States Drugs - Prices - United States Pharmaceutical industry - United States |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Drug shortages, threat to public health persists, despite actions to help maintain product availability |
| Record Nr. | UNINA-9910702660903321 |
Crosse Marcia
|
||
| [Washington, D.C.] : , : United States Government Accountability Office, , 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug store news
| Drug store news |
| Pubbl/distr/stampa | [New York], : Lebhar-Friedman |
| Descrizione fisica | 1 online resource |
| Disciplina | 381/.45/61510973 |
| Soggetto topico |
Drugstores - United States
Pharmaceutical industry - United States Drug Industry Pharmacies Pharmaceutical Services Drugstores Pharmaceutical industry |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | DSN |
| Record Nr. | UNISA-996215770903316 |
| [New York], : Lebhar-Friedman | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Drug store news
| Drug store news |
| Pubbl/distr/stampa | [New York], : Lebhar-Friedman |
| Descrizione fisica | 1 online resource |
| Disciplina | 381/.45/61510973 |
| Soggetto topico |
Drugstores - United States
Pharmaceutical industry - United States Drug Industry Pharmacies Pharmaceutical Services Drugstores Pharmaceutical industry |
| Soggetto genere / forma |
Periodical
Periodicals. |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | DSN |
| Record Nr. | UNINA-9910339569803321 |
| [New York], : Lebhar-Friedman | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina
| Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina |
| Autore | LaMattina John L |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| Descrizione fisica | 1 online resource (156 p.) |
| Disciplina |
338.4761519
615/.19 |
| Soggetto topico |
Drug development - United States
Pharmaceutical industry - United States Drugs - Research - United States |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-118-15896-2
1-281-93930-7 9786611939304 0-470-43467-8 0-470-43465-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cholesterol drugs are unnecessary -- Industry is more interested in 'me-too' drugs than in innovation -- It takes industry too long to discover new drugs -- Drugs are discovered by academia -- New medicines add costs but little benefit -- Big pharma has failed and should learn from biotech success -- The industry invents diseases -- New drugs are less safe than traditional medicines -- Industry spends more on advertising than R&D -- Industry does not care about diseases of the developing world -- Big pharma's day has passed -- Final reflections. |
| Record Nr. | UNINA-9910144118603321 |
|
LaMattina John L
|
||
| Hoboken, N.J., : John Wiley & Sons, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina
| Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina |
| Autore | LaMattina John L |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| Descrizione fisica | 1 online resource (156 p.) |
| Disciplina |
338.4761519
615/.19 |
| Soggetto topico |
Drug development - United States
Pharmaceutical industry - United States Drugs - Research - United States |
| ISBN |
1-118-15896-2
1-281-93930-7 9786611939304 0-470-43467-8 0-470-43465-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cholesterol drugs are unnecessary -- Industry is more interested in 'me-too' drugs than in innovation -- It takes industry too long to discover new drugs -- Drugs are discovered by academia -- New medicines add costs but little benefit -- Big pharma has failed and should learn from biotech success -- The industry invents diseases -- New drugs are less safe than traditional medicines -- Industry spends more on advertising than R&D -- Industry does not care about diseases of the developing world -- Big pharma's day has passed -- Final reflections. |
| Record Nr. | UNINA-9910831068403321 |
|
LaMattina John L
|
||
| Hoboken, N.J., : John Wiley & Sons, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina
| Drug truths [[electronic resource] ] : dispelling the myths about pharma R&D / / John L. LaMattina |
| Autore | LaMattina John L |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| Descrizione fisica | 1 online resource (156 p.) |
| Disciplina |
338.4761519
615/.19 |
| Soggetto topico |
Drug development - United States
Pharmaceutical industry - United States Drugs - Research - United States |
| ISBN |
1-118-15896-2
1-281-93930-7 9786611939304 0-470-43467-8 0-470-43465-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cholesterol drugs are unnecessary -- Industry is more interested in 'me-too' drugs than in innovation -- It takes industry too long to discover new drugs -- Drugs are discovered by academia -- New medicines add costs but little benefit -- Big pharma has failed and should learn from biotech success -- The industry invents diseases -- New drugs are less safe than traditional medicines -- Industry spends more on advertising than R&D -- Industry does not care about diseases of the developing world -- Big pharma's day has passed -- Final reflections. |
| Record Nr. | UNINA-9910841332803321 |
|
LaMattina John L
|
||
| Hoboken, N.J., : John Wiley & Sons, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Economic analysis of the causes of drug shortages
| Economic analysis of the causes of drug shortages |
| Pubbl/distr/stampa | Washington, DC : , : Office of the Assistant Secretary for Planning and Evaluation, Office of Science and Data Policy, U.S. Department of Health and Human Services, , 2011 |
| Descrizione fisica | 1 online resource (19 pages) : color illustrations |
| Collana | ASPE issue brief |
| Soggetto topico |
Pharmaceutical industry - United States
Drug accessibility - United States Drugs - Prices - United States |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910701241003321 |
| Washington, DC : , : Office of the Assistant Secretary for Planning and Evaluation, Office of Science and Data Policy, U.S. Department of Health and Human Services, , 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals [[electronic resource] /] / Steven Garber
| Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals [[electronic resource] /] / Steven Garber |
| Autore | Garber Steven |
| Pubbl/distr/stampa | Santa Monica, Calif., : RAND Institute for Civil Justice, 2013 |
| Descrizione fisica | 1 online resource (117 p.) |
| Disciplina | 338.4761510973 |
| Soggetto topico |
Products liability - Drugs - Economic aspects - United States
Pharmaceutical industry - United States |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title Page; Copyright; Preface; Contents; Figure and Tables; Summary; Acknowledgments; Abbreviations; CHAPTER ONE: Introduction; CHAPTER TWO: Conceptual Framework for the Analyses; Positive Analysis: Effects of Liability Exposure on Company Decisions and Economic Outcomes; Company Decisions and Economic Outcomes; Conceptualizing Company Decision making; What Determines Whether Companies Respond to Liability Exposure?; What Kinds of Conclusions Are Possible from the Positive Analytic Approach?; Normative Analysis: Economic Efficiency of Effects of Liability Exposure; Economic Efficiency
Identifying Sources of Inefficiency CHAPTER THREE: The Legal and Institutional Settings; Food and Drug Administration Regulation; Preapproval Regulations; Post-Market Regulations; Product-Liability Law for Prescription Drugs; Manufacturing Defects; Design Defects; Warnings Defects; Regulatory Compliance Defenses (RCDs); Other Legal Issues and Practices; Personal-Injury Causation; Class Actions Alleging Personal Injuries; Class Actions Alleging Financial Injuries; Judicial Gatekeeping of Expert Evidence; U.S. Supreme Court Decisions on Sizes of Punitive Damages; Medical Monitoring Claims Congregation and Coordination of Related Lawsuits Settlements of Mass Torts; CHAPTER FOUR: Pharmaceutical Mass Torts During the 1990's and 2000's; Mass Torts Resulting in Especially Large Payouts by Defendants; Fen-Phen Diet Pills; Baycol; Rezulin; Vioxx; Hormone Replacement Therapies-Premarin, Provera, and Prempro; Zyprexa; Mass Tort Attempts Resulting in Substantially Smaller Payouts by Defendants; Norplant; Childhood Vaccines and Autism; Other Mass Tort Attempts That Have Largely Failed for Plaintiffs; Summing Up; Mass Drug-Related Injuries; Mass Torts; Financial Incentives to Avoid Liability Roles of Punitive Damages Controversies About Injury Causation; Transaction Costs of Unsuccessful Mass Tort Attempts; CHAPTER FIVE: Preemption of Pharmaceutical Failure-to-Warn Claims; Federal Preemption Law; Purported Economic Effects of Failure-to-Warn Claims; Economic Arguments Supporting Preemption; Economic Arguments Opposing Preemption; Preemption of Failure-to-Warn Claims for Generic Drugs; Would Failure-to-Warn Litigation Pass a Social Cost-Benefit Test?; Sources of Confusion in the Preemption Debate; The Overall Economic Efficiency of FTW Litigation Is Unknown CHAPTER SIX: Incentives Stemming from Other Litigation Affecting Safety and Effectiveness Actions Brought by the U.S. Department of Justice; State Consumer Protection Acts-Background and Controversies; Safety- and Effectiveness-Related Litigation Brought by State Attorneys General; Safety- and Effectiveness-Related Financial-Injury Litigation Brought by Private Parties; Shareholder Suits Pertaining to Pharmaceutical Safety and Effectiveness; Summing Up; CHAPTER SEVEN: In Conclusion; Major Legal Developments Since 1990; Product Liability for Personal Injury Other Litigation Pertaining to Drug Safety and Effectiveness |
| Record Nr. | UNINA-9910220156803321 |
|
Garber Steven
|
||
| Santa Monica, Calif., : RAND Institute for Civil Justice, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Electronic drug labeling : no consensus on the advantages and disadvantages of its exclusive use : report to congressional committees
| Electronic drug labeling : no consensus on the advantages and disadvantages of its exclusive use : report to congressional committees |
| Pubbl/distr/stampa | [Washington, D.C.] : , : United States Government Accountability Office, , 2013 |
| Descrizione fisica | 1 online resource (ii, 20 pages) |
| Soggetto topico |
Drugs - Labeling - Government policy - United States
Electronic records - Government policy - United States Public health - United States Pharmaceutical industry - United States |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Electronic drug labeling |
| Record Nr. | UNINA-9910704967503321 |
| [Washington, D.C.] : , : United States Government Accountability Office, , 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
